Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study

Cabozantinib (XL184), a multi-targeted oral tyrosine kinase inhibitor with activity against MET, VEGFR2, AXL, and other tyrosine kinases, was assessed in a cohort of metastatic breast cancer (MBC) patients in a phase II randomized discontinuation trial (RDT).status: publishe